Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics

Documenti analoghi

• PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
  di: Eduardo Terán, et al.
  Pubblicazione: (2024)
• Machine learning‐based model constructed from ultrasound radiomics and clinical features for predicting HER2 status in breast cancer patients with indeterminate (2+) immunohistochemical results
  di: Meiying Yan, et al.
  Pubblicazione: (2024)
• Evaluating distant recurrence‐free survival and location of metastasis in HER2 + breast cancer by ER status
  di: Damien Kaukonen, et al.
  Pubblicazione: (2025)
• Impact of HER2‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study
  di: Yun Wu, et al.
  Pubblicazione: (2024)
• The evolution and prognostic impact of HER2‐low, HER2‐ultralow, and HER2‐null status in HER2‐negative early breast cancer: A pre– to post–neoadjuvant chemotherapy study
  di: Yibin Qiu, et al.
  Pubblicazione: (2026)